BSBE(SZ:300406)2023-10-24 16:00Financial Performance - The company's revenue for Q3 2023 reached ¥417,357,225.32, representing a year-on-year increase of 1.74%[12] - Net profit attributable to shareholders for Q3 2023 was ¥129,749,230.02, up 21.90% compared to the same period last year[12] - The net profit after deducting non-recurring gains and losses for Q3 2023 was ¥129,817,407.55, reflecting a 21.20% increase year-on-year[12] - Basic earnings per share for Q3 2023 were ¥0.22, a 22.22% increase from the same period last year[12] - Total operating revenue for the current period reached ¥1,233,685,019.60, an increase of 9.93% compared to ¥1,122,220,324.67 in the previous period[46] - Net profit for the current period was ¥368,104,602.24, representing a growth of 33.94% from ¥274,663,272.40 in the previous period[47] - Earnings per share (EPS) increased to ¥0.63, compared to ¥0.46 in the previous period, marking a 37.0% rise[47] - The company reported a net income of $1 billion, with a net profit margin of 19.2%[53] Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥4,966,599,489.37, which is a 7.67% increase from the end of the previous year[12] - The company's total liabilities reached ¥1,394,390,183.63, up from ¥1,344,108,369.97, indicating a 3.43% increase[44] - Total equity attributable to shareholders of the parent company increased to ¥3,578,696,714.44 from ¥3,271,217,726.58, a growth of 9.37%[44] - The company’s total assets amounted to ¥4,966,599,489.37, up from ¥4,612,882,060.21, indicating a growth of 7.66%[44] Cash Flow and Investments - The cash flow from operating activities for the year-to-date period reached ¥366,936,409.47, showing a 42.54% increase year-on-year[12] - Cash flow from investing activities showed a net outflow of CNY 247,398,368.82, an improvement from the previous outflow of CNY 377,655,121.59[39] - The company reported a net cash increase of CNY 62,193,914.64 for the period, contrasting with a decrease of CNY 54,794,052.10 in the previous period[40] Shareholder Information - The total number of common shareholders at the end of the reporting period was 12,284, with the largest shareholder being China Pharmaceutical Investment Co., Ltd., holding 16.63% of shares (97,854,687 shares) [19] - The top ten shareholders held a total of 16,753,419 shares, with Liu Xi being the second-largest shareholder at 11.39% [19] - The total number of shares held by the top ten unrestricted shareholders was 97,854,687 shares [19] Research and Development - Research and development expenses for the current period were ¥109,912,038.83, up from ¥105,432,967.53, reflecting a 4.7% increase[46] - Investment in R&D increased by 20% year-over-year, totaling $400 million for the quarter[53] Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[12] - The company plans to expand into three new international markets by the end of 2024, targeting a potential revenue increase of $1 billion[53] - A strategic acquisition was completed for $1.2 billion, expected to enhance market share by 10%[53] Operational Metrics - The company reported a significant increase in construction in progress, which rose by 120.03% due to investments in a new biological production base project[17] - The company experienced a 225.43% increase in advance payments, primarily due to prepayments for medical diagnostic equipment rentals[17] - Customer retention rate improved to 85%, up from 80% in the previous quarter[53] - Operating expenses increased by 12% year-over-year, totaling $1.5 billion[53]